Inato Launches AI Site Selection

New AI capabilities fuel fast, strategic decisions based on verified data and engagement from 5,500+ research sites globally     

NEW YORK and PARIS, Sept. 15, 2025 /PRNewswire/ -- Today, Inato unveiled new AI capabilities to enhance and accelerate site selection. Sponsors can now use Inato's platform to quickly and easily create and execute data-driven site selection scenarios based on real-time interest and verified data from over 5,500 sites. The new capabilities fill an acute gap for sponsor decisionmakers, arming them with the insights they need to quickly and confidently choose the right mix of sites for each trial.

Site selection is a challenging, high-stakes process for sponsors. It requires months of manual coordination across geographies, spreadsheets, and internal tools to model different scenarios, validate assumptions, and align stakeholders. Existing efforts to fix this process–including purchasing site lists, relying on historical data, or building internal tools–have fallen short, often sending sponsors to the same known sites, to unavailable sites, or back to spreadsheets to craft a new plan. This is both inefficient and increasingly unsustainable as trial competition rises.

Inato has created a new model. Sponsors can engage with Inato's unmatched pool of over 5,500 research sites and access rich, verified profiles from interested sites, which are consistently updated based on the site's activity across the Inato platform. Now, sponsors can also use Inato's new AI site selection analyst to identify the right sites for each trial. Decisionmakers can use plain language to ask the AI analyst to generate, edit, and compare site selection scenarios based on trial goals, including enrollment speed, patient access, and other customized criteria. Unlike other tools or static lists, AI site selection draws on both Inato's extensive site data and real-time site interest and engagement, creating an unparalleled sponsor experience.

"Data-driven site selection has often fallen short, either because the data was outdated, didn't account for site interest, or didn't leave room for sponsor judgment and expertise," said Kourosh Davarpanah, co-founder and CEO of Inato. "With our new AI analyst, decisionmakers have the best of both worlds. They know their trials best and can continue to drive the process, but they now also have an AI analyst that can help them make the best decisions based on qualified, interested sites."

Inato's AI site selection unlocks a number of benefits for sponsors, including:

• Global site engagement: Tap into a vast pool of over 5,500 engaged sites worldwide. Empower decisionmakers to choose the right mix of sites for each trial with real-time site interest and engagement, up-to-date profiles, and data verified by third-party sources–all protected by eCDA workflows trusted by leading sponsors.
• Comprehensive scenario planning: Evaluate all available sites with advanced filtering and use the AI analyst to optimize for the criteria that matter most–including proven performance, fast activation, access to representative patient populations, relevant experience, and more. Easily modify these criteria to understand the impact on trial timeline, enrollment, and number of sites.
• Improved speed: Generate scenarios in minutes using the AI analyst's interactive dashboard, freeing decisionmakers from hours of manual data analysis and enabling them to quickly engage with the right sites.

For more information on AI site selection, click here or schedule a demo here.

About Inato
Inato is on a mission to bring clinical research to every patient, regardless of where they live. The global technology company combines trial planning, site selection, and patient pre-screening into a single AI-enabled platform to transform the way research sites and sponsors work together to advance medical research. Leading pharmaceutical companies trust Inato to enhance trial accessibility and representation, and thousands of research sites leverage the platform to find the right research opportunities for their communities and streamline trial operations. For more information, visit www.inato.com.

CONTACT: Lauren Wry, [email protected]

SOURCE Inato